Julphar’s H1 sales revenue climbs 10.5%

Julphar, a regional leader in the production and distribution of pharmaceutical products, said it registered a sales revenue of Dh696.4 million in the first six months of the year 2013, an increase of 10.5 per cent year-on-year.

By Staff Report

  • Follow us on
  • google-news
  • whatsapp
  • telegram

Published: Sun 28 Jul 2013, 1:04 AM

Last updated: Fri 3 Apr 2015, 7:57 AM

The company said in a statement that its sales during the first half were driven by private market sales, which saw a growth of 13.4 per cent.

“The company continued to show good operational performance during the period. Gross profit during the period was Dh412.1 million, up 8.3 per cent year-on-year. Operating profit for the period, on the other hand, was Dh126.5 million, up 2.8 per cent. Operating profit margin during the period was a robust 18.2 per cent. Profit for the period was Dh116.9 million, up 5.5 per cent,” a statement said.

Julphar chairman Shaikh Faisal bin Saqr Al Qasimi said the financial figures reflected a successful first half of the year for Julphar.

“Maintaining stable financial growth and delivering sustainable healthcare is a key priority of the board,” he added.

Established in 1980, Julphar’s manufacturing network consists of 12 world-class production facilities. Its diverse product portfolio contains over 800 products and targets major therapeutic segments.

In 2012, Julphar became the only company in the Middle East to produce the raw material needed to make insulin, through the launch of a division entirely dedicated to diabetes.

— issacjohn@khaleejtimes.com



More news from